Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
Dr. Deepa Jagadeesh
Advertisement
Articles by Dr. Deepa Jagadeesh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Patients With Cancer Urged to Ask Questions, Take Notes and Do Their Research
2
Fruzaqla and Tyvyt Combo Shows Improved Outcomes in Advanced Kidney Cancer
3
Navigating Life’s Path With Multiple Myeloma
4
FDA OKs Breakthrough Therapy Designation to Sonrotoclax for MCL
5
